The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes

Heart Lung and Circulation

Volumn 12, Issue 1, 2003, Pages 44-50

  Wei, Michael ^a   Ong, Leslie ^a   Smith, Maree T ^a   Ross, Fraser B ^a   Schmid, Katrina ^b   Hoey, Andrew J ^c   Burstow, Darryl ^d   Brown, Lindsay ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Cataracts; Diabetes; Echocardiography; Electrophysiology; Neuropathic pain; Retinopathy

Indexed keywords

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLINDNESS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLE; FLUID INTAKE; FOOD INTAKE; HEART LEFT VENTRICLE; HEART MUSCLE COMPLIANCE; HEART MUSCLE POTENTIAL; HYPERGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; SYSTOLE;

EID: 0043092399     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-2892.2003.00160.x     Document Type: Article

References (25)

1. Butler R, Macdonald TM, Struthers AD, Morris AD. The clinical implications of diabetic heart disease. Eur. Heart J. 1998; 19: 1617-27.
2. Marks JB, Raskin P. Cardiovascular risk in diabetes. A brief review. J. Diabetes Complications 2000; 14: 108-15.
3. Torffvit O, Agardh C-D. The prognosis for type 2 diabetic patients with heart disease. A 10-year observation study of 385 patients. J. Diabetes Complications 2000; 14: 301-306.
4. Torffvit O, Agardh C-D. The impact of metabolic and blood pressure control on incidence and progression of nephropathy. A 10-year study of 385 type 2 diabetic patients. J. Diabetes Complications 2001; 15: 307-13.
5. Voutilainen-Kaunisto RM, Terävirta ME, Uusitupa MIJ, Niskanen LK. Occurrence and predictors of retinopathy and visual acuity in type 2 diabetic patients and control subjects. 10-year follow-up from the diagnosis. J. Diabetes Complications 2001; 15: 24-33.
6. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995; 333: 89-94.
7. Zimmet P, Boyko EJ, Collier GR, de Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann. NY Acad. Sci. 1999; 892: 25-44.
8. Dagogo-Jack S. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch. Int. Med. 1997; 157: 1802-17.
9. Anonymous. The dangerous toll of diabetes. http://www.diabetes.org/ada/facts.asp Accessed 20 April 2001.
10. Valle T, Tuomilehto J, Eriksson J. Epidemiology of NIDDM in Europids. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H (Eds). International Textbook of Diabetes Mellitus, 2nd edn. John Wiley & Sons, London, 1997, pp. 125-42.
11. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol. Rev. 1992; 44: 103-50.
12. Qiang X, Satoh J, Sagara M et al. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-diabetic rats. Diabetologia 1998; 41: 1321-6.
13. Cameron NE, Cotter MA. Diabetes causes an early reduction in autonomic ganglion blood flow in rats. J. Diabetes Complications 2001; 15: 198-202.
14. Gilbert RE, Kelly DJ, Cox AJ et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 2000; 43: 1360-67.
15. Mifsud SA, Allen TJ, Bertram JF et al. Podocyte food process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001; 44: 878-82.
16. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 2001; 133: 687-94.
17. Brown L, Fenning A, Shek A, Burstow D. Reversal of cardiovascular remodeling with candesartan. J. Renin-Angiotensin-Aldosterone System 2001; 2: S141-7.
18. Brown L, Fenning A, Chan V et al. Echocardiographic assessment of cardiac structure and function in rats. Heart, Lung and Circ. 2003; 11: 167-73.
19. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J. Am. Soc. Nephrol. 1999; 10: S143-8.
20. Hoey A, Amos G, Wettwer E, Raven U. Differential effects of BDF 9148 and DPI 201-106 on action potential and contractility in rat and guinea pig myocardium. J. Cardiovasc. Pharmacol. 1994; 23: 907-15.
21. Calcutt NA, Chaplan SR. Spinal pharmacology of tactile allodynia in diabetic rats. Br. J. Pharmacol. 1997; 122: 1478-82.
22. Mitton KP, Dean PA, Dzialoszynski T, Xiong H, Sanford SE, Trevithick JR. Modelling cortical cataractogenesis. 13. Early effects on lens ATP/ADP and glutathione in the streptozotocin rat model of the diabetic cataract. Exper. Eye Res. 1993; 56: 187-98.
23. 2+ currents in ventricular myocytes from rats with chronic diabetes. Am. J. Physiol. 1995; 269: H1288-96.
24. Cagliero E. Characteristics and mechanisms of high-glucose induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes 1991; 40: 102-9.
25. Yu DY, Cringle SJ, Su EN, Yu PK, Jerums G, Cooper ME. Pathogenesis and intervention strategies in diabetic retinopathy. Clin. Exper. Ophthalmol. 2001; 29: 164-6.